Carolyn Starrett Joins Thyme Companies as Executive Vice President for New Ventures

Thyme Companies Welcomes Carolyn Starrett as Executive Vice President

In a significant move to strengthen its leadership in the oncology care sector, Thyme Companies has announced the appointment of Carolyn Starrett as Executive Vice President of New Ventures. This announcement marks an essential step for the company as it aims to tackle persistent challenges within the cancer care landscape, leveraging Starrett's extensive expertise in oncology and data integration.

A Leader with Proven Experience

Carolyn Starrett brings more than two decades of valuable experience to this role, having previously served as the CEO of Flatiron Health, a leading cancer data company. Under her guidance, Flatiron expanded its platform enormously, increasing data records from 400,000 to over 5.5 million, which significantly improved the availability of real-world evidence in oncology.

Robin Shah, Executive Chairman of Thyme Companies, expressed his enthusiasm for Starrett's appointment, stating, "Carolyn has a rare ability to understand where the biggest problems exist across the cancer care journey. She has a track record of building businesses that can solve these problems effectively at scale." Shah emphasized that Starrett's strategic vision and operational expertise would be pivotal as Thyme Companies evolves its approach to cancer care.

Expanding Cancer Care Solutions

In her new position, Starrett will focus on identifying, developing, and scaling new ventures designed to enhance the overall cancer experience for patients. "Joining Thyme Companies represents a chance for me to build a greater understanding of the patient experience and how to navigate the complexities of our healthcare system," Starrett stated. Her commitment to improving cancer care aligns seamlessly with Thyme Companies' mission to address the disconnections in how cancer care is provided, accessed, and funded.

Starrett's extensive experience also includes her tenure as the founder of Starrett Advisory, where she assisted companies working at the intersection of healthcare, data, and artificial intelligence. This background equips her with the insights needed to innovate within the oncology landscape effectively.

Thyme Companies and Its Vision

Thyme Companies is the overarching entity comprised of various businesses aimed at revolutionizing the cancer care experience. Through its flagship operation, Thyme Care, the company has been at the forefront of delivering accountable and comprehensive cancer care.

The appointment of Carolyn Starrett comes at a crucial time, as Thyme Companies has recently secured Series E financing, enabling further expansion into new business lines. With Starrett's leadership, the company anticipates significant advancements that will create more integrated and effective solutions for patients battling cancer.

Concluding Thoughts

As Carolyn Starrett steps into this pivotal role, her extensive knowledge in oncology and commitment to improving patient experiences positions Thyme Companies to redefine how cancer care is delivered. The organization is poised not only to innovate but to enact real change in the cancer care ecosystem, addressing the many challenges faced by patients worldwide. This strategic appointment signals the beginning of a new chapter for Thyme Companies as they pursue their mission of redefining the cancer care paradigm.